Skip to main
PACB
PACB logo

PACB Stock Forecast & Price Target

PACB Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Pacific Biosciences of California Inc. is positioned for potential growth, particularly driven by the positive placement and utilization trends of its sequencing platforms, including Revio and Onso. The company's strong organic growth profile is complemented by strategic acquisitions, enhancing its market position and capabilities in genetic analysis. Despite a cautious approach in its 2024 guidance amid a challenging macroeconomic environment, management's optimistic outlook for a return to growth this year highlights confidence in the company's trajectory.

Bears say

Pacific Biosciences of California Inc faces significant headwinds that could jeopardize its financial outlook, particularly with concerns surrounding stagnant utilization rates and potential weakening demand for new instruments, which threaten its 2026 financial targets. Additionally, ongoing demand weakness in critical markets like China, coupled with tightened research budgets and reduced funding in the biotech sector, further constrains customer purchasing power and adversely impacts potential revenue. Finally, the risk of losing market share to competitors developing superior products adds to the uncertainty surrounding the company's future financial performance.

PACB has been analyzed by 15 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pacific Biosciences of California and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pacific Biosciences of California (PACB) Forecast

Analysts have given PACB a Buy based on their latest research and market trends.

According to 15 analysts, PACB has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.39, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.39, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pacific Biosciences of California (PACB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.